Implementation of hypoxia PET imaging in radiation therapy planning

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 3, 2013, Pages 271-282

  Geets, X ^a   Gregoire V ^a   Lee, J A ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Molecular imaging; Radiation oncology; Radiotherapy

Indexed keywords

CANCER RADIOTHERAPY; HUMAN; HYPOXIA; IRRADIATION; MOLECULAR IMAGING; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ANIMALS; CELL HYPOXIA; HUMANS; MOLECULAR IMAGING; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, IMAGE-GUIDED; TUMOR MICROENVIRONMENT;

EID: 84888813097     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Adkison JB, Khuntia D, Bentzen SM, Cannon GM, Tome WA, Jaradat H et al. Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study. Technol Cancer Res Treat 2008;7:441-7.
2. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28: 2181-90.
3. Bourhis J, Lapeyre M, Tortochaux J, Aghili M, Bourdin S, Lesaunier F et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006;24:2873-8. (Pubitemid 46630588)
4. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-54. (Pubitemid 44292807)
5. Bentzen SM. Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. Cancer Treat Res 2008;139:41-62.
6. Bentzen SM, Gregoire V. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol 2011;21:101-10.
7. Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005;41:1533-41. (Pubitemid 40981834)
8. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. Journal of nuclear medicine: official publication. Society of Nuclear Medicine 2005;46:253-60.
9. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J J Clin Oncol 2006;24:2098-104. (Pubitemid 46622121)
10. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60. (Pubitemid 30317470)
11. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005;6:112-7. (Pubitemid 40197705)
12. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757. (Pubitemid 44832019)
13. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys 2002;54:921-7.
14. Sovik A, Malinen E, Bruland OS, Bentzen SM, Olsen DR. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol 2007;52:499-513. (Pubitemid 46646466)
15. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Seminars in Oncology 2001;28(2 Suppl 8):29-35. (Pubitemid 32522235)
16. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727-35. (Pubitemid 46622039)
17. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24. (Pubitemid 41503384)
18. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56. (Pubitemid 28423786)
19. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer research 1996;56:4509-15. (Pubitemid 26330463)
20. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radio-resistance. Int J Radiat Oncol Biol Phys 2006;65:91-9.
21. Movsas B, Chapman JD, Hanlon AL, itz EM, Greenberg RE, Stobbe C et al. Hypoxic prostate/muscle p02 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002;60:634-9. (Pubitemid 35246449)
22. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008;9:342-51.
23. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21. (Pubitemid 26029371)
24. Christian N, Lee JA, Bol A, De Bast M, Jordan B, Gregoire V. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol 2009;91:101-6.
25. Lapi SE, Volier TF, Welch MJ. Positron emission tomography imaging of hypoxia. PET Clinics 2009;4:39-47.
26. Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB, Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography - a study evaluating [18F]Fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629-37.
27. Mortensen LS, Buus S, Nordsmark M, Bentzen L, Munk OL, Keiding S et al. Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol 2010;49:934-40.
28. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13. (Pubitemid 43086004)
29. Busk M, Horsman MR, Jakobsen S, Hansen KV, Bussink J, van der Kogel A et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol 2009;92:429-36.
30. Valk PE, Bailey DL, Townsend DW, Maisey MN. Positron emission tomography: basic science and clinical practice. New York: Springer Verlag; 2004.
31. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45. (Pubitemid 46909922)
32. Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: voxel size matters. Acta Oncol 2008;47:1201-10.
33. Razifar P, Sandström M, Schnieder H, Långström B, Maripuu E, Bengtsson E et al. Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM. BMC Medical Imaging 2005;5:5.
34. Masuda Y, Kondo C, Matsuo Y, Uetani M, Kusakabe K. Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose. J Nucl Med 2009;50:844-8.
35. Conti M. Effect of randoms on signal-to-noise ratio in TOF PET. IEEE Trans 2006;53:1188-93. (Pubitemid 44109413)
36. Lee JA, Geets X, Gregoire V, Bol A. Edge-preserving filtering of images with low photon counts. IEEE Trans Pattern Anal Mach Intell 2008;30:1014-27. (Pubitemid 351650105)
37. Lee JA. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol 2010;96:302-7.
38. Geets X, Lee JA, Bol A, Lonneux M, Gregoire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging 2007;34:1427-38. (Pubitemid 47312577)
39. Wanet M, Lee JA, Weynand B, De Bast M, Poncelet A, Lacroix V et al. Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with thresholdbased approaches, CT and surgical specimens. Radiother Oncol 2011;98:117-25.
40. Kirov AS, Piao JZ, Schmidtlein CR. Partial volume effect correction in PET using regularized iterative deconvolution with variance control based on local topology. Phys Med Biol 2008;53:2577-91. (Pubitemid 351595083)
41. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004;9 Suppl 5:31-40. (Pubitemid 39658343)
42. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
43. Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol 2003;48:N31-5.
44. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300. (Pubitemid 46589864)
45. Vanderstraeten B, Duthoy W, De Gersem W, De Neve W, Thierens H. [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol 2006;79:249-58. (Pubitemid 44093755)
46. Witte M, Shakirin G, Houweling A, Peulen H, van Herk M. Dealing with geometric uncertainties in dose painting by numbers: introducing the Delta VH. Radiother Oncol 2011;100:402-6.
47. Gregoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer radiotherapie: journal de la Societe francaise de radiotherapie oncologique 2011;15:555-9.
48. McGurk RJ, Bowsher J, Lee JA, Das SK. Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods. Med Phys 2013;40:042501.
49. Duprez F, De Neve W, De Gersem W, Coghe M, Madani I. Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;80:1045-55.
50. Sovik A, Malinen E, Skogmo HK, Bentzen SM, Bruland OS, Olsen DR. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys 2007;68:1496-504. (Pubitemid 47179905)
51. van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:1121-35. (Pubitemid 30345614)
52. Castadot P, Geets X, Lee JA, Christian N, Gregoire V. Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation. Radiother Oncol 2010;95:209-17.
53. Castadot P, Lee JA, Geets X, Gregoire V. Adaptive radiotherapy of head and neck cancer. Semin Radiat Oncol 2010;20:84-93.
54. ts X, Tomsej M, Lee JA, Duprez T, Coche E, Cosnard G et al. Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol 2007;85:105-15.
55. Moore JA, Gordon JJ, Anscher M, Silva J, Siebers JV. Comparisons of treatment optimization directly incorporating systematic patient setup uncertainty with a margin-based approach. Med Phys 2012;39:1102-11.
56. Nohadani O, Seco J, Martin BC, Bortfeld T. Dosimetry robustness with stochastic optimization. Phys Med Biol 2009;54:3421-32.
57. Wendling M, McDermott LN, Mans A, Sonke JJ, van Herk M, Mijnheer BJ. A simple backprojection algorithm for 3D in vivo EPID dosimetry of IMRT treatments. Medical Physics 2009;36:3310-21.
58. Brock KK, Deformable Registration Accuracy C. Results of a multi-institution deformable registration accuracy study (MIDRAS). Int J Radiat Oncol Biol Phys 2010;76:583-96.
59. Castadot P, Lee JA, Parraga A, Geets X, Macq B, Gregoire V. Comparison of 12 deformable registration strategies in adaptive radiation therapy for the treatment of head and neck tumors. Radiother Oncol 2008;89:1-12.
60. Orban de Xivry J, Castadot P, Janssens G, Lee JA, Geets X, Gregoire V et al. Evaluation of the radiobiological impact of anatomic modifications during radiation therapy for head and neck cancer: can we simply summate the dose? Radiother Oncol 2010;96:131-8.
61. Cathier P, Ayache N. New vector field regularization techniques for nonrigid image registration. Biomedical Image Registration 2003;2717: -10.
62. Ruan D, Fessler JA, Roberson M, Balter J, Kessler M. Nonrigid registration using regularization that accommodates local tissue rigidity. Medical Imaging 2006;6144:1-9.
63. Raaymakers BW, Lagendijk JJ, Overweg J, Kok JG, Raaijmakers AJ, Kerkhof EM et al. Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys Med Biol 2009;54:N229-37.
64. Dewhirst MW, Kimura H, Rehmus SW, Braun RD, Papahadjopoulos D, Hong K et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl 1996;27:S247-51. (Pubitemid 26237971)
65. Cardenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW. The pervasive presence of fluctuating oxygenation in tumors. Cancer Research 2008;68:5812-9.
66. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M et al. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 2007;83:406-10. (Pubitemid 46915551)
67. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42. (Pubitemid 350251048)
68. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys 2007;68:515-21. (Pubitemid 46694174)
69. Flynn RT, Bowen SR, Bentzen SM, Rockwell Mackie T, Jeraj R. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol 2008;53:4153-67.
70. Korreman SS, Ulrich S, Bowen S, Deveau M, Bentzen SM, Jeraj R. Feasibility of dose painting using volumetric modulated arc optimization and delivery. Acta Oncol 2010;49:964-71.
71. Berwouts D, Olteanu LA, Duprez F, Vercauteren T, De Gersem W, De Neve W et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. Radiother Oncol 2013.
72. Madani I, Duthoy W, Derie C, De Gersem W, Boterberg T, Saerens M et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:126-35. (Pubitemid 46589860)
73. van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012;104:67-71.